Reversing multidrug resistance by tyrosine kinase inhibitors

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Tyrosine kinase inhibitors (TKIs) are crucial anticancer agents targeting specific signaling pathways.
• Multidrug resistance (MDR), often due to ATP-binding cassette (ABC) transporter overexpression, limits TKI efficacy.
• ABC transporters efflux TKIs, reducing their intracellular concentration and therapeutic effect.

Purpose of the Study:

• To review the mechanisms of MDR in response to TKIs mediated by ABC transporters.
• To explore the potential of TKIs to reverse MDR by inhibiting ABC transporter function.
• To highlight the dual role of TKIs in cancer therapy and overcoming drug resistance.

Main Methods:

• Literature review of studies on TKIs, MDR, and ABC transporters.
• Analysis of research investigating TKI interactions with ABC transporter proteins.
• Synthesis of findings on MDR reversal strategies involving TKIs.

Main Results:

• TKIs targeting specific tyrosine kinases are effective against various cancers.
• Overexpression of ABC transporters is a primary cause of MDR to TKIs.
• Certain TKIs demonstrate the ability to inhibit ABC transporter activity, thereby reversing MDR.

Conclusions:

• Understanding ABC transporter-mediated MDR is critical for optimizing TKI therapy.
• TKIs hold promise not only as direct anticancer agents but also as agents to overcome MDR.
• Further research into TKIs that inhibit ABC transporters could lead to improved cancer treatment regimens.